Cover Image
QR Code

Donor-Transmitted Melanoma: Is It Still Bothering Us?

Opinion Statement: Global organ scarcity remains a severe obstacle because of the rapid growth in the number of patients on the transplant waiting list. Transplant centres strive to raise the number of donors by proposing more mild criteria for donor selection, among them donors with a history of ma...

Full description

Published in:Current Treatment Options in Oncology Vol. 21; no. 5; pp. 1 - 10
Main Author: Abdullayeva, Leila
Format: review Journal Article
Published: Springer Nature May2020
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143660017&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 143660017
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15272729
        3KHC
      jtl: Current Treatment Options in Oncology
      issn: 15272729
      maglogo: N
    pubinfo:
      dt: May2020
      vid: 21
      iid: 5
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        143660017
        143660017
        NLM32328846
        143660017
        10.1007/s11864-020-00740-0
        NLM32328846
        143660017
      ppf: 1
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Donor-Transmitted Melanoma: Is It Still Bothering Us?
      aug:
        au: Abdullayeva, Leila
        affil: Kazakh National Medical University named after S.D. Asfendiyarov, 94 Tole Bi Street, Almaty, Kazakhstan
      sug:
        subj:
          Transplant Donors
          Organ Transplantation Adverse Effects
          Melanoma Etiology
          Neoplasms, Second Primary Etiology
          Combined Modality Therapy
          Neoplasms, Second Primary Epidemiology
          Treatment Outcomes
          Organ Transplantation Statistics and Numerical Data
          Disease Management
          Melanoma Epidemiology
          Neoplasms, Second Primary Diagnosis
          Disease Susceptibility
          Neoplasms, Second Primary Therapy
          Incidence
          Risk Assessment
          Melanoma Diagnosis
          Organ Transplantation Methods
          Melanoma Therapy
          Scales
          Questionnaires
      ab: Opinion Statement: Global organ scarcity remains a severe obstacle because of the rapid growth in the number of patients on the transplant waiting list. Transplant centres strive to raise the number of donors by proposing more mild criteria for donor selection, among them donors with a history of malignancy and older age. Recipients are at hazard of acquiring tumour that existed in the donor at the time of transplantation with the most common cancers been renal cell carcinoma (57%), melanoma (10%), and choriocarcinoma (9%). Tumour origin can be established by PCR-based DNA analysis for microsatellite markers, HLA typing, immunohistochemistry, or fluorescent in situ hybridisation. The general recommendation for treatment of donor-related melanoma is a cessation of immunosuppression therapy to allow rejection of the allograft and its immediate removal. In non-renal transplant patients with life-sustaining organs or if allograft removal is denied, reduction of immunosuppression, chemoradiation therapy, and urgent retransplantation are the only potential strategies. Checkpoint inhibitors were reported to be effective in several cases of donor-transmitted melanoma and now emerge as an innovative option to standard chemotherapy and the potential for cure.
      pubtype: Academic Journal
      doctype:
        review
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N